Display options
Cite
Gabrovska M, Geurs F, Ponette S, et al. Weekly cisplatin may reverse liver dysfunction and jaundice caused by diffuse liver metastases of solid tumors. Hepat Med. 2009;1:9-12doi: 10.2147/hmer.s7574.
Gabrovska, M., Geurs, F., Ponette, S., Ponette, J., Bulte, K., Derveaux, L., & Kempeneers, I. (2009). Weekly cisplatin may reverse liver dysfunction and jaundice caused by diffuse liver metastases of solid tumors. Hepatic medicine : evidence and research, 19-12. https://doi.org/10.2147/hmer.s7574
Gabrovska, M, et al. "Weekly cisplatin may reverse liver dysfunction and jaundice caused by diffuse liver metastases of solid tumors." Hepatic medicine : evidence and research vol. 1 (2009): 9-12. doi: https://doi.org/10.2147/hmer.s7574
Gabrovska M, Geurs F, Ponette S, Ponette J, Bulte K, Derveaux L, Kempeneers I. Weekly cisplatin may reverse liver dysfunction and jaundice caused by diffuse liver metastases of solid tumors. Hepat Med. 2009 Oct 30;1:9-12. doi: 10.2147/hmer.s7574. eCollection 2009. PMID: 24623997; PMCID: PMC3921826.
Copy Download .nbib Format: NLM
Share it on

Hepat Med. 2009 Oct 30;1:9-12. doi: 10.2147/hmer.s7574. eCollection 2009.

Weekly cisplatin may reverse liver dysfunction and jaundice caused by diffuse liver metastases of solid tumors.

Hepatic medicine : evidence and research

M Gabrovska, F Geurs, S Ponette, J Ponette, K Bulte, L Derveaux, I Kempeneers

Affiliations

  1. Dept of Medical Oncology, Regionaal Ziekenhuis Sint Maria, Halle, Belgium.
  2. Dept of Gastroenterology, Pneumology, Regionaal Ziekenhuis Sint Maria, Halle, Belgium.
  3. Dept of Pneumology, Regionaal Ziekenhuis Sint Maria, Halle, Belgium.
  4. Dept of Surgery, Regionaal Ziekenhuis Sint Maria, Halle, Belgium.

PMID: 24623997 PMCID: PMC3921826 DOI: 10.2147/hmer.s7574

Abstract

Few data are available on patient management in jaundice caused by liver metastases of solid tumors (nonbreast and noncolon origin). We report the first patient series consecutively treated with cisplatin weekly in patients with severe jaundice and liver failure due to underlying metastatic neoplasms. In 4 out of 8 cases, liver function tests were reversed and jaundice disappeared, permitting subsequent standard chemotherapy. The other 4 patients died 3 to 5 weeks after admission, illustrating the extent and severity of the underlying neoplasm.

Keywords: chemotherapy; cisplatin; jaundice; liver failure; metastases

References

  1. Clin Oncol (R Coll Radiol). 2005 Jun;17(4):249-57 - PubMed
  2. QJM. 2008 Dec;101(12):949-53 - PubMed
  3. Int J Gynecol Cancer. 2008 Mar-Apr;18(2):228-34 - PubMed
  4. Ther Clin Risk Manag. 2008 Dec;4(6):1363-6 - PubMed
  5. Cancer Chemother Pharmacol. 1997;40(4):347-52 - PubMed
  6. Mayo Clin Proc. 2004 Feb;79(2):169-75 - PubMed
  7. J Med Case Rep. 2008 Aug 19;2:279 - PubMed
  8. Br J Cancer. 2002 Jan 7;86(1):19-25 - PubMed
  9. Tumori. 2006 Jul-Aug;92(4):354-7 - PubMed
  10. World J Surg Oncol. 2008 Sep 30;6:104 - PubMed
  11. Br J Cancer. 1993 Oct;68(4):789-92 - PubMed
  12. Ann Oncol. 1992 Aug;3 Suppl 3:57-62 - PubMed
  13. World J Gastroenterol. 2006 Apr 21;12(15):2466-8 - PubMed
  14. Lancet Oncol. 2008 Dec;9(12):1181-90 - PubMed
  15. Cancer Chemother Pharmacol. 2003 Nov;52(5):367-70 - PubMed
  16. Br J Cancer. 2009 Jan 13;100(1):44-9 - PubMed
  17. J Gastrointest Cancer. 2008;39(1-4):26-8 - PubMed
  18. Onkologie. 2009 Jul;32(7):400-4 - PubMed

Publication Types